Company Encyclopedia
View More
name
Roche
RHHBY.US
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions.
4.359 T
RHHBY.USMarket value -Rank by Market Cap -/-

Financial Score

14/11/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking2/180
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE32.73%A
    • Profit Margin14.85%A
    • Gross Margin75.67%A
  • Growth ScoreB
    • Revenue YoY8.89%B
    • Net Profit YoY-7.74%C
    • Total Assets YoY11.12%B
    • Net Assets YoY12.89%B
  • Cash ScoreB
    • Cash Flow Margin673.33%C
    • OCF YoY8.89%B
  • Operating ScoreB
    • Turnover0.67B
  • Debt ScoreD
    • Gearing Ratio65.13%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    European stocks "Eleven Arhats" closing report | On Friday, SAP fell 3.2%, while this week Novo Nordisk AS, Sanofi, Roche, LVMH Group, and Astrazeneca rose at least about 5%

    On November 14th, European stocks closed with SAP down 3.21% and Novo Nordisk down 2.39%, but up 6.82% for the week. GlaxoSmithKline, Novartis, Nestlé, Sanofi, Roche Holding, ASML Holding, L'Oréal, LVMH Group, and AstraZeneca all saw varying degrees of increase this week, with LVMH Group and AstraZeneca rising more than 5%

    Wallstreetcn·
    US
    RHHBY
    -1.25%
    US
    NVO
    -1.83%
    US
    AZN
    +0.55%
    Wallstreetcn·
    US
    RHHBY
    -1.25%
    US
    NVO
    -1.83%
    US
    AZN
    +0.55%

    Poherdy, first biosimilar to Roche’s Perjeta, scores FDA nod

    The FDA has approved Poherdy, developed by Henlius Biotech and licensed to Organon, as an interchangeable biosimilar to Roche's Perjeta for HER2-positive breast cancer. This approval allows pharmacists to substitute Poherdy for Perjeta without another prescription. Roche's Perjeta sales have declined due to a shift to its fixed-dose combination, Phesgo. Roche faces patent challenges from Henlius and Organon, and more biosimilars may enter the market as the FDA aims to reduce development costs.

    Fiercepharma·
    US
    OGN
    -1.18%
    US
    RHHBY
    -1.25%
    HK
    02696
    +3.63%
    Fiercepharma·
    US
    OGN
    -1.18%
    US
    RHHBY
    -1.25%
    HK
    02696
    +3.63%

    Deutsche Bank Remains a Hold on Roche Holding AG (RHHVF)

    Deutsche Bank analyst Emmanuel Papadakis has maintained a Hold rating on Roche Holding AG (RHHVF) with a price target of CHF265.00. Papadakis, a 4-star analyst with a 53.29% success rate, focuses on the Healthcare sector. The consensus for Roche Holding AG is also a Hold, with a price target consensus of $348.40.

    Tip Ranks·
    US
    RHHBY
    -1.25%
    Tip Ranks·
    US
    RHHBY
    -1.25%

    Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche | RHHBY Stock News

    A survey commissioned by Roche reveals that 31% of European millennials aged 29-42 have postponed or missed cervical cancer screenings, significantly higher than other age groups. Factors contributing to this trend include fears of pain and embarrassment, as well as challenges in balancing work and caregiving responsibilities. The findings emphasize the need for tailored interventions, such as self-sampling options, to improve screening attendance. Roche aims to eliminate cervical cancer through collective action and increased awareness of the importance of regular screenings.

    StockTitan·
    US
    RHHBY
    -1.25%
    StockTitan·
    US
    RHHBY
    -1.25%

    Health Care Roundup: Market Talk

    Find insight on AstraZeneca, Pfizer, Roche and more in the latest Market Talks covering Health Care.

    MSN·
    UK
    AZN
    0.00%
    US
    PFE
    -2.83%
    US
    RHHBY
    -1.25%
    MSN·
    UK
    AZN
    0.00%
    US
    PFE
    -2.83%
    US
    RHHBY
    -1.25%